What is your approach to oligometastatic HER2 positive breast cancer, particularly after excellent clinical response in all sites of disease to trastuzumab, pertuzumab, and a taxane?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • Her2+ • NCI-CCC Breast Tumor Board Question

Answer from: Medical Oncologist at Academic Institution

The question of optimal treatment of low burden metastatic HER2-positive breast cancer and complete or near complete response to systemic therapy remains open. The two potential strategies are to continue systemic therapy with HER2-blocking antibodies +/- endocrine therapy or to continue the s...

Comments

Medical Oncologist at NYU Winthrop Hospital
CLEOPATRA trial -- I will continue trastuzumab and...

Medical Oncologist at University of California Irvine Medical Center
I agree with the above discussions. Recent update ...

Medical Oncologist at William Beaumont Hospital
For this subset of patients with oligometastatic d...

Medical Oncologist at University of Utah Huntsman Cancer Institute
I've done both. If the tumor is ER-positive,...

Medical Oncologist at Warren Alpert Medical School of Brown University
While there is evidence of higher pCR rates with T...

Related Questions